PolyPid (NASDAQ:PYPD – Get Free Report) and Silk Road Medical (NASDAQ:SILK – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Profitability
This table compares PolyPid and Silk Road Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PolyPid | N/A | -572.69% | -110.25% |
| Silk Road Medical | -29.02% | -35.47% | -20.67% |
Institutional & Insider Ownership
26.5% of PolyPid shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 3.9% of Silk Road Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PolyPid | N/A | N/A | -$23.86 million | ($12.64) | -0.26 |
| Silk Road Medical | $177.13 million | 6.06 | -$55.74 million | ($1.37) | -19.87 |
PolyPid has higher earnings, but lower revenue than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
PolyPid has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for PolyPid and Silk Road Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PolyPid | 0 | 0 | 1 | 0 | 3.00 |
| Silk Road Medical | 2 | 7 | 1 | 0 | 1.90 |
PolyPid currently has a consensus price target of $14.00, suggesting a potential upside of 329.45%. Silk Road Medical has a consensus price target of $21.50, suggesting a potential downside of 21.01%. Given PolyPid’s stronger consensus rating and higher possible upside, equities research analysts clearly believe PolyPid is more favorable than Silk Road Medical.
Summary
PolyPid beats Silk Road Medical on 7 of the 12 factors compared between the two stocks.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
About Silk Road Medical
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
